Available via license: CC BY-NC-ND 4.0
Content may be subject to copyright.
Respiratory Medicine Case Reports 48 (2024) 102004
Available online 7 March 2024
2213-0071/© 2024 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contents lists available at ScienceDirect
Respiratory Medicine Case Reports
journal homepage: www.elsevier.com/locate/rmcr
Case Report
Paclitaxel-induced acute fibrinous and organizing pneumonitis in
early breast cancer: A case report
Piyarat Limpawittayakul a,*, Supinda Petchjorm b, Worawong Chueansuwan c,
Wanvisa Boonfueang d
aDivision of Medical Oncology, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand
bDivision of Pathology, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand
cDivision of Infectious Diseases, Phramongkutklao Hospital, Bangkok, Thailand
dDivision of Pulmonary Medicine, Ramkhamhaeng Hospital, Bangkok, Thailand
ARTICLE INFO
Handling Editor: DR AC Amit Chopra
Keywords:
Paclitaxel
Pneumonitis
Interstitial lung disease
ABSTRACT
Background: Paclitaxel is a chemotherapeutic drug widely used in breast cancer treatment. While
common side effects are possible, paclitaxel-induced pneumonitis is rare, with an estimated inci-
dence of 1%–5% and a high mortality rate.
Case presentation: A 57-year-old Thai woman diagnosed with stage II right breast cancer. She re-
ceived adjuvant chemotherapy comprising doxorubicin and cyclophosphamide, followed by
weekly paclitaxel. After the ninth paclitaxel cycle, she developed acute respiratory failure.
Transbronchial biopsies revealed acute fibrinous and organizing pneumonitis. The patient was
placed in prone position. Following the administration of dexamethasone, her symptoms im-
proved. However, while reducing the dexamethasone dosage, she developed new-onset dyspnea
as well as Takotsubo cardiomyopathy. Intravenous methylprednisolone 500 mg/day was admin-
istered for 3 days followed by transition to intravenous dexamethasone and slow tapering to
prednisolone. Prednisolone was gradually tapered and eventually discontinued after 3 months.
Conclusions: Paclitaxel-induced pneumonitis is a rare complication. The diagnosis should be
considered in any patient who develops respiratory symptoms while receiving paclitaxel. Acute
fibrinous and organizing pneumonitis is a rare type of interstitial pneumonitis with high recur-
rence and mortality rates. High-dose steroids are needed to treat this type of pneumonitis.
1. Background
Paclitaxel, a chemotherapeutic agent originally derived from the bark of the North American yew tree, Taxus brevifolia, has been
used primarily in ovarian and breast cancer treatment [1]. Notably, paclitaxel has demonstrated significant activity in various other
cancers, including small-cell and non-small-cell lung cancer, head and neck cancers, and gastric cancer [1]. The cellular mechanism of
paclitaxel involves inducing mitotic block by stabilizing microtubules, thereby reducing the dynamic nature of these cytoskeletal
structures [2].
Common adverse effects of paclitaxel comprise neutropenia, alopecia, peripheral neuropathy, nausea with vomiting, arthralgia,
myalgia, and hypersensitivity reactions [3,4]. The latter is triggered by its diluent, polyoxyethylated castor oil, known as Cremophor
EL, and the adverse effects can be mitigated through premedication with steroids and histamine receptor antagonists [3,4]. While
common side effects are well-known, paclitaxel-induced pneumonitis is rare, cautiously estimated to occur at a rate of 1%–5% [5].
* Corresponding author.
E-mail address: piyarat.lim@cra.ac.th (P. Limpawittayakul).
https://doi.org/10.1016/j.rmcr.2024.102004
Received 7 October 2023; Accepted 6 March 2024
Respiratory Medicine Case Reports 48 (2024) 102004
2
P. Limpawittayakul et al.
To the best of our knowledge, our case is the first reported instance of paclitaxel-induced acute fibrinous and organizing pneu-
monitis (AFOP). In this report, we describe the patient's clinical symptoms, radiographic and computed tomography (CT) findings,
and biopsy-confirmed AFOP resulting from paclitaxel administration. This unique case demonstrates the complexity of treatment in
drug-induced AFOP, as the symptoms temporarily improved upon steroid administration but deteriorated again upon tapering. The
patient provided informed consent.
2. Case presentation
A 57-year-old Thai woman was diagnosed with early-stage right breast cancer in February 2021. Her medical history included hy-
pertension, and she was a non-smoker. On May 3, 2021, she underwent right total mastectomy with sentinel lymph node dissection.
Pathology results revealed grade III invasive ductal carcinoma, with the mass measuring 3.1 cm in diameter. Immunohistochemical
analysis indicated negative expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2,
with a Ki67 index of 50%. Sentinel lymph node dissection showed no metastasis in the four dissected lymph nodes. This resulted in a
final pathologic stage of pT2N0M0, classified as stage II.
Following the surgery, the patient underwent four cycles of adjuvant chemotherapy with doxorubicin and cyclophosphamide, ad-
ministered at 3-week intervals. Subsequently, a regimen of weekly paclitaxel at 80 mg/m2over 1 hour was planned for 12 cycles. A
standard premedication protocol comprising dexamethasone, chlorpheniramine, and ondansetron was administered prior to the pa-
clitaxel infusion, followed by a 3-day course of dexamethasone at 8 mg per day post-infusion. The patient completed nine cycles of
weekly paclitaxel, which was generally well-tolerated, except for the development of grade II peripheral neuropathy after the fourth
cycle.
Approximately 1 week after completing the ninth cycle, the patient experienced exertional dyspnea that persisted for 2 weeks with
no cough or fever. Her symptoms worsened progressively, prompting her referral to the emergency room on the day scheduled for her
tenth cycle of paclitaxel. At this point, her oxygen saturation was 75%–82% on room air, necessitating intubation. Physical examina-
tion revealed rhonchi in the right lung. A complete blood count revealed a white blood cell count of 4.7 × 10³/mL, with 85% neu-
trophils and no peripheral eosinophilia.
3. CT, computed tomography
A chest radiograph revealed multifocal reticulonodular patchy opacities in both lungs (Fig. 1A). Chest CT demonstrated newly de-
veloped multifocal consolidations and ground glass opacities in both lungs. Lesions were distributed along the peribronchovascular
regions, suggesting an infectious or inflammatory process. Additionally, several subcentimeter right paratracheal, paraaortic, subcari-
nal, and bilateral hilar lymph nodes were visible, with diameters measuring up to 0.9 cm. These were considered reactive lymph
nodes. Furthermore, concentric intraluminal filling defects were observed in the anterior, medial, and posterior basal segmental
branches of the right lower lobar pulmonary arteries, as well as the posterior basal segmental branch of the left lower lobar pul-
monary artery, indicative of acute pulmonary embolism (Fig. 1B).
Empirical antibiotic therapy comprising meropenem, levofloxacin, oseltamivir, and trimethoprim-sulfamethoxazole was initiated
to address potential bacterial/viral pneumonias and Pneumocystis carinii pneumonia. Enoxaparin treatment was also initiated for the
acute pulmonary embolism. The patient was placed on a ventilator with the fraction of inspired oxygen set at 1.0. Arterial blood gas
analysis indicated a pH of 7.319, partial pressure of carbon dioxide of 36, partial pressure of oxygen of 60.6, and an arterial pO2(P)
from arterial blood gas divided by FIO2(F) or P/F Ratio was 60.6.
Throughout her hospital stay, the patient remained afebrile, and the scant sputum was clear in color. To ascertain the cause of the
pneumonitis, bronchoscopy with bronchoalveolar lavage and transbronchial biopsies were performed the following day. Notably, the
results of throat swab real-time polymerase chain reaction (RT-PCR) testing for a panel of 33 viruses, including influenza and severe
acute respiratory syndrome coronavirus 2, were negative. Microscopic examination of the bronchoalveolar lavage using Wright's,
acid-fast bacilli, and modified acid-fast bacilli stains revealed no identifiable pathogens. Additionally, aerobic bacterial and fungal
cultures from the lavage were negative. Further testing, namely PCR for mycobacteria and Aspergillus (galactomannan) antigen, with
Fig. 1. A: Chest X-ray showing multifocal reticulonodular patchy opacities in both lungs. B: Chest CT chest showing newly developed multifocal consolidations and
ground glass opacities involving both lungs, with a peribronchovascular distribution.
Respiratory Medicine Case Reports 48 (2024) 102004
3
P. Limpawittayakul et al.
an immunofluorescence assay and PCR for Pneumocystis, yielded negative results. Hemoculture results were also negative for all speci-
mens.
Transbronchial biopsies revealed alveolar septal thickening, which was attributed to increased fibroblastic stroma and mononu-
clear inflammatory cells. Notably, frequent interalveolar fibrin leakage was observed, with a varying admixture primarily composed
of macrophages, a smaller number of lymphocytes, and occasional neutrophils. Pneumocyte hyperplasia with reactive changes was
also evident. Bronchial tissue exhibited mild lymphocyte infiltration with no neutrophil infiltration. No granulomas, foamy material,
fungi, or viral inclusions were detected. These pathological observations consistently aligned with moderate subacute lung injury,
morphologically congruent with AFOP (Fig. 2).
Following the bronchoscopy, the patient's symptoms worsened, leading to a diagnosis of paclitaxel-induced pneumonitis accom-
panied by severe acute respiratory distress syndrome. To address the patient's deteriorating condition, the muscle relaxant
cisatracurium and the sedative drugs fentanyl and midazolam were administered, and she was placed in the prone position. Intra-
venous dexamethasone at a dosage of 10 mg every 12 hours was initiated, resulting in observable symptom improvement, as evi-
denced by a chest X-ray that revealed reduced lung infiltrations compared with the earlier images (Fig. 3A). However, upon reducing
the dexamethasone dosage to 8 mg every 12 hours on the 10th day of admission, the patient experienced new-onset dyspnea. A subse-
quent chest X-ray indicated progression of multifocal reticulonodular patchy infiltrations (Fig. 3B). Concomitantly, she developed
tachy-brady arrhythmia and hypotension. The concentrations of the cardiac biomarkers creatine kinase-MB, troponin-T, and N-
terminal pro-brain natriuretic peptide were elevated. Echocardiography revealed a left ventricular ejection fraction of 10%–15%,
leading to a diagnosis of Takotsubo cardiomyopathy (stress-induced cardiomyopathy). High-dose inotropic drugs, specifically norepi-
nephrine, were introduced to stabilize the hemodynamics. The patient also received a temporary pacemaker to manage the arrhyth-
mia. Intravenous methylprednisolone 500 mg was administered for 3 days, followed by transition to intravenous dexamethasone.
Fig. 2. A and Bshow the range of alveolar septal thickening from mild to moderate due to increased fibroblastic stroma (red arrow) and mononuclear inflamma-
tory cell infiltration. Cshows multiple areas of intra-alveolar fibrin leakage with mononuclear infiltration (blue arrows) and pneumocyte type II hyperplasia with
reactive atypia (red arrows). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Fig. 3. A: Chest X-ray after dexamethasone administration showing some improvement in the infiltrations. B: Chest X-ray after tapering the dose of dexametha-
sone showing increased infiltration in both lungs. C: Chest X-ray after slowly tapering the dexamethasone and eventually stopping prednisolone for 4 months
showing near-normal findings.
Respiratory Medicine Case Reports 48 (2024) 102004
4
P. Limpawittayakul et al.
Dexamethasone was continued for 30 days, after which dexamethasone was changed to prednisolone. A tracheostomy was performed
owing to the prolonged need for intubation. After 41 days of admission, the patient was successfully weaned from the ventilator.
Considering the severity of the adverse effects, the decision was made to discontinue the paclitaxel. Upon discharge, the patient re-
ceived prednisolone 0.5 mg/kg/day. Subsequent chest X-ray showed improvement in the previous findings. Follow-up echocardiogra-
phy before discharge demonstrated an improved left ventricular ejection fraction of 60%. Prednisolone was gradually tapered and
eventually discontinued 3 months after discharge. Initially requiring oxygen supplementation at home for 2 months, the patient even-
tually regained the ability to ambulate without the need for supplemental oxygen. A chest X-ray obtained 4 months after discontinu-
ing prednisolone revealed near-normal lung findings (Fig. 3C).
4. Discussion
Paclitaxel-induced pneumonitis represents a rare yet potentially fatal complication, underscoring the importance of prompt recog-
nition and management. Any patient undergoing paclitaxel treatment who presents with dyspnea and/or fever warrants considera-
tion for this complication, and early investigation through chest imaging is paramount.
The proposed risk factors for paclitaxel-induced pneumonitis are pre-existing pulmonary fibrosis, prior emphysematous changes,
concurrent radiation therapy, and combination therapy with other chemotherapy agents [6,7]. Intriguingly, factors such as smoking
status, age, and performance status have not demonstrated significant associations with the risk of pneumonitis [6,7]. Notably, the
risk of pneumonitis with paclitaxel appears to be linked to dosing schedules rather than the total dose administered. The CALGB 9840
randomized phase III trial comparing weekly and every-3-weeks paclitaxel for metastatic breast cancer revealed that the weekly
schedule resulted in a higher occurrence of grade ≥3 dyspnea during therapy (7% for weekly vs. 4% for every 3 weeks) [8].
Anoop et al. performed a prospective study in India and reported that among patients who received weekly paclitaxel, 10% devel-
oped acute interstitial pneumonitis after one cycle, 5% after two cycles, 3% after three cycles, 8% after five cycles, 3% after seven cy-
cles, 3% after eight cycles, and 3% after twelve cycles [9]. The median number of cycles required to induce interstitial lung disease
was five [9].
The precise mechanism underlying paclitaxel-induced pneumonitis remains incompletely understood. Two hypotheses have been
postulated: an allergic type (type I hypersensitivity reaction) and a cell-mediated cytotoxic type (type IV hypersensitivity reaction).
Type I hypersensitivity reactions involve immunoglobulin E-mediated immune responses and histamine or vasoactive substance re-
lease from basophils and mast cells. This hypersensitivity reaction is characterized by acute dyspnea, bronchospasm, hypotension,
and an erythematous rash (typically developing shortly after drug administration). This type is observed in up to 30% of cases of pa-
clitaxel-associated adverse reactions, and the rate decreases to 1%–3% with steroid premedication. In contrast, type IV hypersensitiv-
ity reactions, also known as delayed-type hypersensitivity, result from T-cell-mediated reactions. Cytokine release activates T-cells or
macrophages, leading to tissue damage. Typically, this type manifests as an acute-subacute clinical course over a few hours to 2 weeks
and is characterized by bilateral pulmonary infiltrates, resembling the presentation in our case [10,11].
Notably, our case lacked peripheral eosinophilia. Peripheral eosinophilia or neutrophilia is not commonly noted, the presence of
hypereosinophilia may indicate a favorable prognosis [12].
The characteristic features observed in our case's chest CT images mirrored those of similar cases, featuring diffuse ground-glass
opacities, reticular opacities, thickened septal lines, and irregular airspace consolidations. The findings from the transbronchial
biopsy, which revealed interstitial pneumonitis predominantly infiltrated by mononuclear inflammatory cells, lend further support to
the proposed hypothesis of a type IV hypersensitivity reaction as the mechanism behind the paclitaxel-induced pneumonitis in our pa-
tient.
Of particular interest, the pathological pattern indicated AFOP, which is an infrequent histological presentation of interstitial
pneumonitis characterized by intra-alveolar fibrin deposits and widespread organizing pneumonia within alveolar ducts and bronchi-
oles. While this pattern was initially described by Travis in 2002, its etiological spectrum includes connective tissue disorders, drug
reactions, occupational exposures, and infections [13,14]. Clinically, this type of interstitial lung disease presents in two patterns: an
acute and fulminant course with rapid progression to respiratory failure and death, or a subacute, less fulminating course with even-
tual recovery. The prognosis is generally grim, marked by a high mortality rate ranging between 50% and 60% [15]. A retrospective
study from Japan by Onishi et al. found that AFOP has a high recurrence rate following steroid treatment, ranging between 60% and
76% and necessitating higher corticosteroid doses during recurrences compared with the first episode [16,17].
Diagnosing paclitaxel-induced pneumonitis entails combining clinical and radiological patterns and exposure history, and exclud-
ing other causes of diffuse pulmonary infiltration. In our case, the presence of typical clinical, radiological, and pathological findings
with the absence of evidence for other infectious agents, led to the diagnosis of paclitaxel-induced pneumonitis.
Corticosteroids remain the cornerstone of paclitaxel-induced pneumonitis treatment. In our case, prompt initiation of dexametha-
sone led to brief symptom improvement. However, attempting to reduce the steroid dose triggered symptom progression and exacer-
bation. A similar case has been reported wherein lung oxygenation improved temporarily upon steroid administration but deterio-
rated again upon tapering [4]. Given the histopathological confirmation of AFOP in our case, and the associated high recurrence rate,
we transitioned the patient to pulse methylprednisolone, administering 500 mg/day for 3 days after symptoms worsened. Recommen-
dations for grade 4 (very severe, life-threatening, or disabling) drug-induced interstitial pneumonitis advise pulse methylpred-
nisolone, followed by high-dose steroids (prednisolone 1–2 mg/kg/day) for 2–4 weeks with gradual tapering thereafter [18]. The
severity of pulmonary injury dictates the duration of corticosteroid therapy, with our case necessitating a total course of approxi-
mately 5 months.
Respiratory Medicine Case Reports 48 (2024) 102004
5
P. Limpawittayakul et al.
5. Conclusions
•Paclitaxel-induced pneumonitis remains a rare complication of paclitaxel therapy.
•Any patient receiving paclitaxel therapy who exhibits respiratory symptoms accompanied by a diffuse bilateral interstitial
pattern should be aware of paclitaxel-induced pneumonitis.
•Prompt administration of steroids is essential upon diagnosis. Since AFOP represents an uncommon subtype of interstitial
pneumonitis with high recurrence and mortality rates, high-dose steroids are imperative to effectively manage this variant of
pneumonitis.
Ethics approval and consent to participate
This study was meticulously conducted with strict adherence to the ethical principles outlined in the Declaration of Helsinki
guidelines governing research involving human subjects. The study protocol underwent thorough review and received approval from
the Ethics Committee for Human Research at the Chulabhorn Research Institute (Certificate No.085/2566). Informed consent was
provided by the patient.
Funding
We are pleased to acknowledge the support extended by the Chulabhorn Royal Academy, Thailand, which provided funding for
the completion of this study.
Authors’contributions
Data curation, Conceptualization, original draft; and Writing - review & editing, P.L. (Piyarat Limpawittayakul); Supervision, S.P.;
Supervision, W.C. and W.B. All authors have read and agreed to the published version of the manuscript.
Declaration of competing interest
The authors hereby declare that they have no known competing financial interests or personal relationships that could potentially
influence the work presented in this manuscript.
Acknowledgements
We extend our heartfelt gratitude to the patient and her family for their invaluable participation in this research endeavor. We
would also like to acknowledge the editing assistance provided by Jane Charbonneau, DVM, from Edanz (www.edanz.com/ac) in re-
fining the draft of this manuscript.
List of abbreviations
CT Computed tomography
RT-PCR Real-time polymerase chain reaction
AFOP Acute fibrinous and organizing pneumonitis
References
[1] R. Foa, L. Norton, A.D. Seidman, Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity, Int. J. Clin. Lab. Res. 24 (1994)
6–14 https://doi.org/10.1007/BF02592403, PMID: 7910054.
[2] M.A. Jordan, Mechanism of action of antitumor drugs that interact with microtubules and tubulin, Curr Med Chem Anticancer Agents 2 (2002) 1–7https://
doi.org/10.2174/1568011023354290, PMID: 12678749.
[3] A. Khan, D. McNally, P.J. Tutschka, S. Bilgrami, Paclitaxel-induced acute bilateral pneumonitis, Ann. Pharmacother. 31 (1997) 1471–1474 https://doi.org/
10.1177/106002809703101205, PMID: 9416383.
[4] G.S. Wang, K.Y. Yang, R.P. Perng, Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere), Br. J. Cancer 85 (2001) 1247–1250 https://
doi.org/10.1054/bjoc.2001.2071, PMID: 11720456; PMCID: PMC2375237.
[5] B. Vahid, P.E. Marik, Pulmonary complications of novel antineoplastic agents for solid tumors, Chest 133 (2008) 528–538 https://doi.org/10.1378/chest.07-
0851, PMID: 18252919.
[6] K. Long, K. Suresh, Pulmonary toxicity of systemic lung cancer therapy, Respirology 25 (2020) 72–79 https://doi.org/10.1111/resp.13915, Epub 2020 Jul 29.
PMID: 32729207.
[7] A. Tamiya, T. Naito, S. Miura, S. Morii, A. Tsuya, Y. Nakamura, et al., Interstitial lung disease associated with docetaxel in patients with advanced non-small cell
lung cancer, Anticancer Res. 32 (2012) 1103–1106 PMID: 22399640.
[8] A.D. Seidman, D. Berry, C. Cirrincione, L. Harris, H. Muss, P.K. Marcom, et al., Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for
metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results
of Cancer and Leukemia Group B protocol 9840, J. Clin. Oncol. 26 (2008) 1642–1649 https://doi.org/10.1200/JCO.2007.11.6699, PMID: 18375893.
[9] T.M. Anoop, R. Joseph, P. Unnikrishnan, F. Thomas, M. Venugopal, Taxane-induced acute interstitial pneumonitis in patients with breast cancer and outcome of
taxane rechallenge, Lung India 39 (2022) 158 https://doi.org/10.4103/lungindia.lungindia_126_21, PMID: 35259799; PMCID: PMC9053915.
[10] S. Nagata, Y. Maehara, N. Ueda, Y. Yoshida, H. Matsuda, Severe interstitial pneumonitis associated with the administration of taxanes, J. Infect. Chemother. 16
(2010) 340–344 https://doi.org/10.1007/s10156-010-0058-4, Epub 2010 Mar 31. PMID: 20354889.
[11] M. Abbas, M. Moussa, H. Akel, Type I hypersensitivity reaction, 2023 Jan, in: StatPearls [Internet], StatPearls Publishing, Treasure Island (FL, 2022 Jul 18 PMID:
32809396.
[12] L. Ardolino, B. Lau, I. Wilson, J. Chen, L. Borella, E. Stone, et al., Case report: paclitaxel-Induced pneumonitis in early breast cancer: a single institution
experience and review, Front. Oncol. 11 (2021), 701424 https://doi.org/10.3389/fonc.2021.701424, PMID: 34249762; PMCID: PMC8261280.
[13] M.B. Beasley, T.J. Franks, J.R. Galvin, B. Gochuico, W.D. Travis, Acute fibrinous and organizing pneumonia: a histologic pattern of lung injury and possible
Respiratory Medicine Case Reports 48 (2024) 102004
6
P. Limpawittayakul et al.
variant of diffuse alveolar damage, Arch. Pathol. Lab Med. 126 (2002) 1064–1070 https://doi.org/10.5858/2002-126-1064-AFAOP, PMID: 12204055.
[14] M.B. Beasley, T.J. Franks, J.R. Galvin, B. Gochuico, W.D. Travis, Acute fibrinous and organizing pneumonia: a histological pattern of lung injury and possible
variant of diffuse alveolar damage, Arch. Pathol. Lab Med. 126 (9) (2002 Sep) 1064–1070 https://doi.org/10.5858/2002-126-1064-AFAOP, PMID: 12204055.
[15] J.Y. Kim, K.W. Doo, H.J. Jang, Acute fibrinous and organizing pneumonia: imaging features, pathologic correlation, and brief literature review, Radiol Case Rep
13 (2018) 867–870 https://doi.org/10.1016/j.radcr.2018.04.028, PMID: 30174771; PMCID: PMC6116343.
[16] Y. Onishi, T. Kawamura, T. Higashino, R. Mimura, H. Tsukamoto, S. Sasaki, Clinical features of acute fibrinous and organizing pneumonia: an early histologic
pattern of various acute inflammatory lung diseases, PLoS One 16 (2021), e0249300 https://doi.org/10.1371/journal.pone.0249300, PMID: 33793625; PMCID:
PMC8016294.
[17] M. Nishino, S.K. Mathai, D. Schoenfeld, S.R. Digumarthy, R.L. Kradin, Clinicopathologic features associated with relapse in cryptogenic organizing pneumonia,
Hum. Pathol. 45 (2014) 342–351 https://doi.org/10.1016/j.humpath.2013.09.010, Epub 2013 Oct 3. PMID: 24342432.
[18] P. Conte, P.A. Ascierto, G. Patelli, R. Danesi, A. Vanzulli, F. Sandomenico, et al., Drug-induced interstitial lung disease during cancer therapies: expert opinion on
diagnosis and treatment, ESMO Open 7 (2022), 100404 https://doi.org/10.1016/j.esmoop.2022.100404, Epub 2022 Feb 24. PMID: 35219244; PMCID:
PMC8881716.
